Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
📍 The outcome
Scribe Therapeutics, a gene-editing company focused on cardiovascular diseases, filed for a $75 million IPO on the Nasdaq. The company's stockholders include Eli Lilly.
The story quieted without a definitive conclusion in the coverage.
Epilogue added 43d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Scribe Therapeutics, a biotech company focused on cardiovascular diseases, has filed for a $75 million IPO. The company, based in Alameda, uses gene-editing technology to fight cholesterol.
Coverage from Renaissance Capital, The Business Journals, Investing.com, Moomoo, and Endpoints News highlights Scribe Therapeutics' stockholder list, which includes Eli Lilly. The IPO will be listed on Nasdaq, but coverage does not yet specify when it will take place or how the public will respond.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 46d ago.
Who reported it (5)
- SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO renaissancecapital.com · 47d ago
- Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches The Business Journals · 47d ago
- Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com Investing.com South Africa · 47d ago
- Scribe Therapeutics Stockholders Include Eli Lilly Moomoo · 47d ago
- Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs Endpoints News · 47d ago broke it first
Quick answers
What is Scribe Therapeutics' focus?
Cardiovascular diseases
How much is Scribe Therapeutics seeking in its IPO?
$75 million
Who is a notable stockholder in Scribe Therapeutics?
Eli Lilly
People, places & organizations
Topics
Related trends
JBS Proposes to Acquire Remaining Stake in Pilgrim’s Pride
JBS has proposed acquiring the remaining publicly traded shares of Pilgrim's Pride, which could result in a Nasdaq delisting.
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
As Elon Musk Promises The Future, Tesla Stock Slides Into The Past
Tesla stock has erased a full year of gains following a difficult post-earnings week and an analyst downgrade.
Three Prices Where SpaceX Stock Is a Buy
SpaceX stock experiences significant market volatility, trading at a discount to its IPO price while analysts debate potential entry points for investors.
Memory-Chip Stocks Micron, SK Hynix Drop After China Rival’s IPO
Memory-chip stocks are tumbling as China's CXMT makes a massive market debut, becoming the most valuable China-listed company.